Evolution of ARDS biomarkers: Will metabolomics be the answer?

Area of Science:

• Pulmonary and Critical Care Medicine
• Biomarker Discovery
• Metabolomics

Background:

• Acute respiratory distress syndrome (ARDS) diagnosis relies on clinical, laboratory, and radiological findings, lacking a specific diagnostic test.
• Past ARDS biomarker development has faced challenges, prompting research into disease subphenotyping using clinical characteristics and blood biomarkers.
• Current subphenotyping approaches show correlations but haven't fully elucidated ARDS etiology, necessitating alternative research methodologies.

Purpose of the Study:

• To review the current state of metabolomics research in acute respiratory distress syndrome (ARDS).
• To discuss the advancements and significant obstacles in ARDS metabolomics research.
• To highlight the potential of metabolomics in understanding ARDS pathophysiology and identifying diagnostic biomarkers.

Main Methods:

• Literature review of ARDS metabolomics studies.
• Analysis of methodologies, sample sizes, control cohorts, specimen types, and measurement techniques used in existing studies.
• Evaluation of validation status of identified metabolomics biomarkers.

Main Results:

• ARDS metabolomics studies have primarily focused on identifying differentiating metabolites for diagnosis.
• Significant variability exists across studies regarding sample size, control group selection, specimen type, and analytical techniques.
• A lack of proper validation hinders the identification of true metabolomics biomarkers for ARDS.

Conclusions:

• Metabolomics research, despite being in its early stages, holds considerable promise for uncovering the underlying biological mechanisms of ARDS.
• Standardization and rigorous validation of metabolomics studies are crucial for advancing the field and developing reliable ARDS biomarkers.
• Metabolomics has the potential to significantly enhance our current understanding of ARDS and improve diagnostic capabilities.